Yearly hypertension screening in women with a history of pre-eclampsia: a cost-effectiveness analysis
Yearly hypertension screening in women with a history of pre-eclampsia: a cost-effectiveness analysis
复制标题
DOI:
10.1007/s12471-015-0760-z
复制
发表时间:
2015-12-01
影响因子:
2
通讯作者:
Maas, A. H. E. M.
中科院分区:
文献类型:
--
作者:
Drost, J. T.;Grutters, J. P. C.;Maas, A. H. E. M.
Background Women with a history of preeclampsia are at increased risk for future hypertension and cardiovascular disease (CVD); until now it is not clear whether preventive measures are needed.Methods A decision-analytic Markov model was constructed to evaluate healthcare costs and effects of screening and treatment (100 % compliance) for hypertension post preeclampsia based on the available literature. Cardiovascular events and CVD mortality were defined as health states. Outcomes were measured in absolute costs, events, life-years and quality-adjusted life-years (QALYs). Sensitivity and threshold analyses were performed to address uncertainty.Results Over a 20-year time horizon, events occurred in 7.2 % of the population after screening, and in 8.5 % of the population without screening. QALYs increased from 16.37 (no screening strategy) to 16.40 (screening strategy), an increment of 0.03 (95 % CI 0.01; 0.05) QALYs. Total expected costs were (sic) 8016 in the screening strategy, and (sic) 9087 in the none screening strategy (expected saving of (sic) 1071 (95 % CI -3146;-87) per person).Conclusion Annual hypertension screening and treatment in women with a history of preeclampsia may save costs, for at least a similar quality of life and survival due to prevented CVD compared with standard care.